Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147503 | 0.85 | GSK3B (0.72) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL15988673 | 0.84 | GSK3B (0.73) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL10844749 | 0.83 | GSK3B (0.70) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL11606690 | 0.81 | GSK3B (0.68) | GSK3BCES2CES1DAOALDH1A1 | |
| SCHEMBL3472612 | 0.81 | GSK3B (0.68) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL847050 | 0.81 | GSK3B (0.68) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL3998532 | 0.81 | GSK3B (1.00) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL1359642 | 0.80 | GSK3B (0.67) | GSK3BGAAKDM4EALDH1A1POLB | |
| SCHEMBL18153171 | 0.78 | GSK3B (0.64) | GSK3BDAOPOLBKMT2AMEN1 | |
| SCHEMBL6847233 | 0.78 | GSK3B (0.63) | GSK3BCES2CES1DAONPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261327-A1 | 2-(HETEROARYL-THIO)-1-(HETEROARYL)ETHANONE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3556755-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-0571253-B1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR (FR) | 1998-11-04 | — | — | EP | disclosed |
| EP-0816352-A1 | Bi-aryl heterocyclic compounds and their use in human or veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-01-07 | — | — | EP | disclosed |
| US-5639756-A | ANTIDIABETIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5623073-A | ANTIDIABETIC AGENT | ADIR ET COMPAGNIE (FR) | 1997-04-22 | — | — | US | disclosed |
| US-5502070-A | INSECTICIDES, MITICIDES, PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| EP-0591785-A1 | Substituted 3,4-hetarylpyrazolines, process for their preparation and their use as pesticides | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0571253-A1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR ET COMPAGNIE (FR) | 1993-11-24 | — | — | EP | disclosed |
| US-4596815-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | disclosed |
| US-4105663-A | HYPOTENSIVE, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-08-08 | — | — | US | disclosed |
| US-4093628-A | HYPOTENSIVE AGENTS, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | GSK3B 3281/4885CES2 3987/4885CES1 3169/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | GSK3B 865/4885CES2 417/4885CES1 79/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | GSK3B 3281/4885CES2 3987/4885CES1 3169/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | GSK3B 865/4885CES2 417/4885CES1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.